Patient characteristics for samples used to obtain array data
Patient . | Translocation . | Sex . | Age,y . | WBC count × 109/L . | Prednisone . | CD20, % . | Immunophenotype . | BCR/ABL . |
|---|---|---|---|---|---|---|---|---|
| 100 | BCR/ABL | M | 3 | 273.0 | PGR | 70 | Pre | e 1 a2 (m) |
| 101 | BCR/ABL | M | 14 | 243.0 | PPR | 30 | Common | e 1 a2 (m) |
| 102 | BCR/ABL | M | 9 | 270.0 | PPR | 9 | Common | e 1 a2 (m) |
| 103 | BCR/ABL | F | 7 | 37.8 | PGR | 24 | Common | e 1 a2 (m) |
| 104 | BCR/ABL | M | 8 | 24.7 | PGR | 1 | Common | e 1 a2 (m) |
| 121 | BCR/ABL | M | 7 | 44.5 | PGR | 10 | Common | b2a2(M) |
| 122 | BCR/ABL | M | 14 | 271.7 | PGR | 86 | Pre | b3a2(M) |
| 132 | BCR/ABL | M | 14 | 35.8 | PGR | 78 | Common | e 1 a2 (m) |
| 133 | BCR/ABL | F | 14 | 7.5 | PGR | 53 | Common | e 1 a2 (m) |
| 134 | BCR/ABL | F | 5 | 2.7 | PGR | 6 | Pre | e 1 a2 (m) |
| 137 | BCR/ABL | F | 11 | 92.7 | PPR | 2 | Mixed | e 1 a2 (m) |
| 138 | BCR/ABL | M | 7 | 12.8 | PGR | 38 | Common | e 1 a2 (m) |
| 139 | BCR/ABL | F | 1 | 23.6 | PGR | 41 | Pre | e 1 a2 (m) |
| 105 | MLL/AF4 | M | 12 | 364.8 | PGR | 0 | Pro | — |
| 107 | MLL/AF4 | F | 0 | 704.0 | PGR | 2 | Pro | — |
| 108 | MLL/AF4 | F | 3 | 91.6 | PGR | 0 | Pro | — |
| 123 | MLL/AF4 | M | 0 | 206.8 | PGR | 1 | Pro | — |
| 124 | MLL/AF4 | M | 0 | 419.0 | PGR | 0 | Pro | — |
| 125 | MLL/AF4 | F | 0 | 220.0 | PGR | 0 | Pro | — |
| 130 | MLL/AF4 | F | 0 | 366.0 | PPR | 0 | Pro | — |
| 131 | MLL/AF4 | M | 0 | 1 050.0 | PPR | 0 | Pro | — |
| 135 | MLL/AF4 | F | 12 | 698.0 | PPR | 0 | Pro | — |
| 136 | MLL/AF4 | F | 16 | 148.0 | PGR | 0 | Pre | — |
| 140 | MLL/AF4 | M | 0 | 562.0 | PGR | 0 | Pro | — |
| 109 | TEL/AML 1 | F | 6 | 3.9 | PGR | 2 | Common | — |
| 110 | TEL/AML 1 | F | 4 | 1.7 | PGR | 66 | Common | — |
| 111 | TEL/AML 1 | M | 12 | 3.5 | PGR | 5 | Mixed | — |
| 112 | TEL/AML 1 | F | 3 | 26.1 | PGR | 6 | Common | — |
| 113 | TEL/AML 1 | M | 4 | 6.2 | PGR | 7 | Pre | — |
| 114 | TEL/AML 1 | F | 5 | 106.5 | PPR | 9 | Common | — |
| 115 | TEL/AML 1 | F | 7 | 0.3 | PGR | 20 | Common | — |
| 116 | TEL/AML 1 | M | 4 | 31.5 | PPR | 9 | Common | — |
| 117 | TEL/AML 1 | M | 6 | 5.5 | PGR | 1 | Pre | — |
| 118 | TEL/AML 1 | M | 5 | 4.5 | PGR | 2 | Common | — |
| 119 | TEL/AML 1 | F | 3 | 35.3 | PGR | 2 | Common | — |
| 120 | TEL/AML 1 | F | 4 | 2.6 | PGR | 8 | Common | — |
| 127 | TEL/AML 1 | M | 4 | 130.0 | PPR | 3 | Common | — |
| 128 | TEL/AML 1 | M | 3 | 11.0 | PPR | 7 | Common | — |
Patient . | Translocation . | Sex . | Age,y . | WBC count × 109/L . | Prednisone . | CD20, % . | Immunophenotype . | BCR/ABL . |
|---|---|---|---|---|---|---|---|---|
| 100 | BCR/ABL | M | 3 | 273.0 | PGR | 70 | Pre | e 1 a2 (m) |
| 101 | BCR/ABL | M | 14 | 243.0 | PPR | 30 | Common | e 1 a2 (m) |
| 102 | BCR/ABL | M | 9 | 270.0 | PPR | 9 | Common | e 1 a2 (m) |
| 103 | BCR/ABL | F | 7 | 37.8 | PGR | 24 | Common | e 1 a2 (m) |
| 104 | BCR/ABL | M | 8 | 24.7 | PGR | 1 | Common | e 1 a2 (m) |
| 121 | BCR/ABL | M | 7 | 44.5 | PGR | 10 | Common | b2a2(M) |
| 122 | BCR/ABL | M | 14 | 271.7 | PGR | 86 | Pre | b3a2(M) |
| 132 | BCR/ABL | M | 14 | 35.8 | PGR | 78 | Common | e 1 a2 (m) |
| 133 | BCR/ABL | F | 14 | 7.5 | PGR | 53 | Common | e 1 a2 (m) |
| 134 | BCR/ABL | F | 5 | 2.7 | PGR | 6 | Pre | e 1 a2 (m) |
| 137 | BCR/ABL | F | 11 | 92.7 | PPR | 2 | Mixed | e 1 a2 (m) |
| 138 | BCR/ABL | M | 7 | 12.8 | PGR | 38 | Common | e 1 a2 (m) |
| 139 | BCR/ABL | F | 1 | 23.6 | PGR | 41 | Pre | e 1 a2 (m) |
| 105 | MLL/AF4 | M | 12 | 364.8 | PGR | 0 | Pro | — |
| 107 | MLL/AF4 | F | 0 | 704.0 | PGR | 2 | Pro | — |
| 108 | MLL/AF4 | F | 3 | 91.6 | PGR | 0 | Pro | — |
| 123 | MLL/AF4 | M | 0 | 206.8 | PGR | 1 | Pro | — |
| 124 | MLL/AF4 | M | 0 | 419.0 | PGR | 0 | Pro | — |
| 125 | MLL/AF4 | F | 0 | 220.0 | PGR | 0 | Pro | — |
| 130 | MLL/AF4 | F | 0 | 366.0 | PPR | 0 | Pro | — |
| 131 | MLL/AF4 | M | 0 | 1 050.0 | PPR | 0 | Pro | — |
| 135 | MLL/AF4 | F | 12 | 698.0 | PPR | 0 | Pro | — |
| 136 | MLL/AF4 | F | 16 | 148.0 | PGR | 0 | Pre | — |
| 140 | MLL/AF4 | M | 0 | 562.0 | PGR | 0 | Pro | — |
| 109 | TEL/AML 1 | F | 6 | 3.9 | PGR | 2 | Common | — |
| 110 | TEL/AML 1 | F | 4 | 1.7 | PGR | 66 | Common | — |
| 111 | TEL/AML 1 | M | 12 | 3.5 | PGR | 5 | Mixed | — |
| 112 | TEL/AML 1 | F | 3 | 26.1 | PGR | 6 | Common | — |
| 113 | TEL/AML 1 | M | 4 | 6.2 | PGR | 7 | Pre | — |
| 114 | TEL/AML 1 | F | 5 | 106.5 | PPR | 9 | Common | — |
| 115 | TEL/AML 1 | F | 7 | 0.3 | PGR | 20 | Common | — |
| 116 | TEL/AML 1 | M | 4 | 31.5 | PPR | 9 | Common | — |
| 117 | TEL/AML 1 | M | 6 | 5.5 | PGR | 1 | Pre | — |
| 118 | TEL/AML 1 | M | 5 | 4.5 | PGR | 2 | Common | — |
| 119 | TEL/AML 1 | F | 3 | 35.3 | PGR | 2 | Common | — |
| 120 | TEL/AML 1 | F | 4 | 2.6 | PGR | 8 | Common | — |
| 127 | TEL/AML 1 | M | 4 | 130.0 | PPR | 3 | Common | — |
| 128 | TEL/AML 1 | M | 3 | 11.0 | PPR | 7 | Common | — |
The prednisone heading lists the initial response to prednisone and a single dose of intrathecal methotrexate: prednisone poor response (PPR) or prednisone good response (PGR). 17 CD20 was determined by flow cytometry. Immunophenotype was assigned on the basis of the criteria of the European Group for the Immunological Characterization of Leukemia. 26 The BCR/ABL heading lists whether a particular sample has the minor breakpoint p 190 (m) or the major breakpoint p210 (M). 27 WBC indicates white blood cell; and —, not applicable.